Lexicon Pharmaceuticals
Headquarters country
United States
Registry sponsor category
Industry
- Other names
- Lexicon Pharmaceuticals
- Company name
- Lexicon Pharmaceuticals
- Organisation type
- Industry
- Registered legal name
- LEXICON PHARMACEUTICALS, INC.
- US industry code (SIC)
- Pharmaceutical preparations
- Registry sponsor category
- Industry
- Website
- http://www.lexpharma.com/
- SEC filer number (CIK)
- 0001062822
- Wikidata ID
- Q6537727
Related records
Trials (68)
- A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
- A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome
- A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy Subjects
- A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects
- A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone
- A Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Healthy Subjects
- A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis
- A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control
- A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative Colitis
- A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
- A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy Subjects
- A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics
- A Thorough QT Study of Telotristat Etiprate
- An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects
- An Open-Label Food Effect Study of Telotristat Etiprate
- An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects
- An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males
- Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 Tablets
- CKM For Safe Use of SGLT2i in Type 1 Diabetes
- Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes